New device enables rapid identification of brain cancer type and tumor margin - (Science Daily via NewsPoints Desk)

  • A study published in Science and Technology of Advanced Materials suggests a micro-sized device has been developed for quick, accurate identification of a mutation strongly associated with gliomas, Science Daily reported Wednesday.

  • The immuno-wall microdevice features a chip with an attached highly specific antibody, HMab-2, that binds to the protein produced by the gene in which the mutation has occurred.

  • "The immuno-wall determines whether a sample is positive for a specific mutation in the isocitrate dehydrogenase 1 gene, which is present in around 70 percent to 80 percent of grade II and III gliomas," said coauthor Toshihiro Kasama.

  • "Our results for a range of cancerous cell lines and actual tumour samples both positive and negative for this mutation were very promising," Kasama added.

  • Lead author Akane Yamamichi noted that "our data indicate that a sample with just 500 cells or 500 ng of protein is sufficient to give a positive result."

  • Yamamichi said "the key to success in the immuno-wall assay is that we, luckily, have HMab-2, the highly specific antibody to the mutant IDH1. This means the immuno-wall can identify the margins of tumours where only low numbers of cancerous cells are present."

Did you like this article?